March 25, 2020 / 1:43 AM / 9 days ago

BRIEF-Botanix Pharmaceuticals Says BTX 1204 Did Not Meet Primary Endpoint In Phase 2 Study

March 25 (Reuters) - Botanix Pharmaceuticals Ltd:

* BTX 1204 DID NOT MEET PRIMARY ENDPOINT IN PHASE 2 STUDY FOR SAFETY & EFFICACY IN PATIENTS WITH MODERATE ATOPIC DERMATITIS

* NOT IN A POSITION TO PROVIDE IMMEDIATE GUIDANCE AS TO FUTURE OF BTX 1204 PROGRAM Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below